Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
Eman Al Sulais, 1 Turki AlAmeel 2 1Department of Medicine, Royal Commission Hospital, Jubail, Saudi Arabia; 2Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi ArabiaCorrespondence: Eman Al SulaisDepartment of Medicine, Royal Commission Hospital, P.O. Box 496, Jubail, Qatif 3191...
Saved in:
Main Authors: | Al Sulais E, AlAmeel T |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/8b0f7337174e4d028df9e7df5dafc9aa |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
by: Rawla P, et al.
Published: (2018) -
Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
by: Al-Meghaiseeb ES, et al.
Published: (2016) -
Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017) -
Seminars in inflammatory bowel disease
Published: (2001) -
A practical guide about biosimilar data for health care providers treating inflammatory diseases
by: Markenson J, et al.
Published: (2017)